The global gastroretentive drug delivery systems outsourcing market accounted for USD 1.44 billion in 2023 and is expected to reach USD 3.04 billion by 2034 with a CAGR of 7.01% during the forecast period 2024-2034. The market will grow due to the rising prevalence of chronic diseases, advances in pharmaceutical research and development, increased demand for controlled drug release, a greater emphasis on patient-centered healthcare, regulatory support for innovative drug delivery systems, technological advances in drug delivery, and a focus on research efficiency and time-to-market.
Controlled drug release systems, such as GRDDS, are gaining popularity because of their ability to sustain therapeutic medication levels in the body for an extended length of time, enhancing patient compliance and reducing dose frequency. This need is prompting pharmaceutical corporations to outsource the development of GRDDS to specialized vendors. For instance, in November 2023, Catalent announced that it had acquired RheinCell Therapeutics, a German-based cell treatment startup, therefore expanding its medication delivery and development capabilities. The acquisition is probably going to improve Catalent's standing in the medication distribution industry.
By dosage form, the tablets segment accounted for the highest revenue-grossing segment in the global gastro-retentive drug delivery systems outsourcing market in 2023 owing to the increasing prevalence of chronic diseases and the growing demand for long-acting drug formulations. For instance, in October 2023, Lonza declared that it has partnered with a top pharmaceutical business to design and produce drug delivery systems that are gastro-retentive. The goal of this partnership is to take advantage of Lonza's experience with drug delivery systems. Additionally, the microspheres segment is predicted to grow at the fastest CAGR during the forecast period owing to advantages such as controlled drug release, improved patient compliance, and advancements in manufacturing technologies.
By type, the floating drug delivery systems segment accounted for the highest revenue-grossing segment in the global gastro-retentive drug delivery systems outsourcing market in 2023 owing to the increased focus on improving bioavailability, prolonged gastric residence time, and enhanced therapeutic efficacy. For instance, in September 2023, Eudragit IR 2, a new gastroretentive drug delivery system from Evonik, was introduced. Its purpose is to administer a controlled release of active pharmaceutical ingredients into the stomach. This breakthrough demonstrates Evonik's dedication to developing novel medication delivery systems. Additionally, the bioadhesive drug delivery systems segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for localized drug delivery, improved patient convenience, and advancements in adhesive technologies.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global gastro-retentive drug delivery systems outsourcing market in 2023 owing to the increased patient admissions, higher prescription rates, and greater availability of specialized medications. For instance, in August 2023 Colorcon unveiled a brand-new gastroretentive medication delivery platform that provides configurable options for formulations with controlled release. The objective of this platform is to improve patient compliance and tackle issues related to oral medicine delivery. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of e-commerce, convenience of home delivery, and expanding digital healthcare infrastructure.
North American region is anticipated to have the highest revenue share during the forecast period owing to a well-established pharmaceutical industry, high healthcare expenditure, and increasing investment in research and development. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding pharmaceutical market, increasing healthcare infrastructure investments, and rising prevalence of chronic diseases. For instance, in July 2023, Quotient Sciences reported that at its Nottingham, UK location, it had increased the scope of its formulation development and manufacturing capabilities for gastroretentive drug delivery systems.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Controlled drug release systems, such as GRDDS, are gaining popularity because of their ability to sustain therapeutic medication levels in the body for an extended length of time, enhancing patient compliance and reducing dose frequency. This need is prompting pharmaceutical corporations to outsource the development of GRDDS to specialized vendors. For instance, in November 2023, Catalent announced that it had acquired RheinCell Therapeutics, a German-based cell treatment startup, therefore expanding its medication delivery and development capabilities. The acquisition is probably going to improve Catalent's standing in the medication distribution industry.
By dosage form, the tablets segment accounted for the highest revenue-grossing segment in the global gastro-retentive drug delivery systems outsourcing market in 2023 owing to the increasing prevalence of chronic diseases and the growing demand for long-acting drug formulations. For instance, in October 2023, Lonza declared that it has partnered with a top pharmaceutical business to design and produce drug delivery systems that are gastro-retentive. The goal of this partnership is to take advantage of Lonza's experience with drug delivery systems. Additionally, the microspheres segment is predicted to grow at the fastest CAGR during the forecast period owing to advantages such as controlled drug release, improved patient compliance, and advancements in manufacturing technologies.
By type, the floating drug delivery systems segment accounted for the highest revenue-grossing segment in the global gastro-retentive drug delivery systems outsourcing market in 2023 owing to the increased focus on improving bioavailability, prolonged gastric residence time, and enhanced therapeutic efficacy. For instance, in September 2023, Eudragit IR 2, a new gastroretentive drug delivery system from Evonik, was introduced. Its purpose is to administer a controlled release of active pharmaceutical ingredients into the stomach. This breakthrough demonstrates Evonik's dedication to developing novel medication delivery systems. Additionally, the bioadhesive drug delivery systems segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for localized drug delivery, improved patient convenience, and advancements in adhesive technologies.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global gastro-retentive drug delivery systems outsourcing market in 2023 owing to the increased patient admissions, higher prescription rates, and greater availability of specialized medications. For instance, in August 2023 Colorcon unveiled a brand-new gastroretentive medication delivery platform that provides configurable options for formulations with controlled release. The objective of this platform is to improve patient compliance and tackle issues related to oral medicine delivery. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of e-commerce, convenience of home delivery, and expanding digital healthcare infrastructure.
North American region is anticipated to have the highest revenue share during the forecast period owing to a well-established pharmaceutical industry, high healthcare expenditure, and increasing investment in research and development. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding pharmaceutical market, increasing healthcare infrastructure investments, and rising prevalence of chronic diseases. For instance, in July 2023, Quotient Sciences reported that at its Nottingham, UK location, it had increased the scope of its formulation development and manufacturing capabilities for gastroretentive drug delivery systems.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Dosage Form, Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Gastro retentive Drug Delivery Systems Outsourcing Market Report 2023 - 2034
Gastro retentive Drug Delivery Systems Outsourcing Market Analysis & Forecast by Dosage Form 2023 - 2034 (Revenue USD Bn)
- Tablets
- Liquid
- Microspheres
- Capsule
- Others
Gastro retentive Drug Delivery Systems Outsourcing Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- High-Density Systems
- Expandable Drug Delivery Systems
- Bioadhesive Drug Delivery Systems
- Floating Drug Delivery Systems
- Others
Gastro retentive Drug Delivery Systems Outsourcing Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Gastro retentive Drug Delivery Systems Outsourcing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Gastro Retentive Drug Delivery Systems Outsourcing Market: Dosage Form Estimates & Trend Analysis
8. Gastro Retentive Drug Delivery Systems Outsourcing Market: Type Estimates & Trend Analysis
9. Gastro Retentive Drug Delivery Systems Outsourcing Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Gastro Retentive Drug Delivery Systems Outsourcing Market
12. Europe Global Gastro Retentive Drug Delivery Systems Outsourcing Market
13. Asia Pacific Global Gastro Retentive Drug Delivery Systems Outsourcing Market
14. Latin America Global Gastro Retentive Drug Delivery Systems Outsourcing Market
15. MEA Global Gastro Retentive Drug Delivery Systems Outsourcing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Catalent
- Patheon (now part of Thermo Fisher Scientific)
- Lonza Group
- Recipharm
- Jubilant Pharma
- Piramal Pharma Solutions
- Dr. Reddy's Laboratories
- Aenova Group
- Fareva
- Metrics Contract Services
- Cambrex
- Siegfried Group
- Almac Group
